(E)-3-<4-(3-pyridylmethyl)phenyl>-2-methylacrylic acid hydrochloride | 75986-80-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-<4-(3-pyridylmethyl)phenyl>-2-methylacrylic acid hydrochloride
• 英文别名: (E)-3-[4-(pyridin-3-ylmethyl)phenyl]methacrylic acid hydrochloride；(E)-3-[4-(3-pyridylmethyl)phenyl)methacrylic acid hydrochloride；2-Methyl-3-[4-(3-pyridylmethyl)phenyl]propenoic acid hydrochloride；2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid hydrochloride；(E)-2-methyl-3-[4-(pyridin-3-ylmethyl)phenyl]prop-2-enoic acid;hydrochloride
• CAS: 75986-80-0
• 化学式: C₁₆H₁₅NO₂*ClH
• 分子量: 289.762
• InChiKey: BTGWEKWSISKKFW-NBYYMMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  50.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (E)-2-methyl-3-[4-(pyridin-3-ylmethyl)phenyl]acrylic acid ethyl ester 以78%的产率得到
  参考文献：
  名称：

  TANOUCHI, TADAO;KAWAMURA, MASANORI;OHYAMA, ISAO;KAJIWARA, IKUO;IGUCHI, YO+, J. MED. CHEM., 1981, 24, N 10, 1149-1155

  摘要：

  DOI：

文献信息

• Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
  申请人：Glidden Paul F.

  公开号：US20090324710A1

  公开（公告）日：2009-12-31

  Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

  提供了预防和治疗方法，用于通过给予药剂，包括anagrelide和anagrelide衍生物，将循环血小板数量降至低于正常水平或低于正常水平，以抑制血管闭塞事件，包括栓塞。提供了包含这些药剂的方法和制药制剂。
• CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR
  申请人：Glidden Paul F.

  公开号：US20130022671A1

  公开（公告）日：2013-01-24

  Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

  提供了预防和治疗方法，以抑制血管闭塞事件，包括栓塞，通过给予药物，包括阿格列酯和阿格列酯衍生物，将循环血小板数量降低到低于正常水平或低于正常水平的水平。提供了包含这些药物的方法和制药制剂。
• Cinnamic acid derivatives, processes for the preparation thereof and pharmaceutical compositions
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0153678A1

  公开（公告）日：1985-09-04

  Novel cinnamic acid derivatives of the formula: wherein R1 is a lower alkyl group, R2 is hydrogen atom or a lower alkyl group, and Y is hydroxymethylene, a lower alkoxymethylene, aminomethylene, hydroxyiminomethylene, a halogenomethylene or carbonyl group, and processes for the preparation thereof. Said compounds (I) show in pharmaceutical compositions an inhibitory effect upon thromboxane A2 synthetase and are useful as a platelet aggregation inhibitor and an antithrombotic agent for the prophylaxis and treatment of various thromboses.

  式中 R1 为低级烷基，R2 为氢原子或低级烷基，Y 为羟基亚甲基、低级烷氧基亚甲基、氨基亚甲基、羟基亚氨基亚甲基、卤素亚甲基或羰基的新型肉桂酸衍生物及其制备工艺。 上述化合物 (I) 在药物组合物中显示出对血栓素 A2 合成酶的抑制作用，可用作血小板聚集抑制剂和抗血栓剂，用于预防和治疗各种血栓。
• MULTI-LAYERED INJECTABLE SELF-ASSEMBLING PEPTIDE SCAFFOLD HYDROGELS FOR LONG-TERM SUSTAINED RELEASE OF HUMAN ANTIBODIES
  申请人：Massachusetts Institute of Technology

  公开号：EP2968135A1

  公开（公告）日：2016-01-20
• JP2011524416A
  申请人：——

  公开号：JP2011524416A

  公开（公告）日：2011-09-01